Industry experts reinforce not putting all eyes on the patient.
There is a lot of talk about money. Inflation, recession, interest rates, which we feel most directly in our trips to the grocery store, going to events, or just keeping our cars running. All of this makes people anxious, and, in turn, serves to reinforce the negative churn in the markets. In this issue of Applied Clinical Trials, our main feature discusses inflation in relation to running global clinical trials. And indicators are, yes, around inflation, funding, and investment, but as a short-term problem. In the long-term, global clinical trials are not in danger of slowing down.
Other trends in clinical trials are signaling longer-term fiscal impact. Let’s look at the pandemic. While its silver lining was a forced pivot to decentralized trials, DCTs still have an aura of the unknown. Which technologies should be implemented? How are sites going to be trained or compensated for technological shifts? If participants are mostly monitored at home, how does that shift clinical trial agreements and contracts? But also, when does the use of technology in DCTs become a burden to patients?
Another long-standing debit in the clinical trials industry is the cost of low participant enrollment and retention in clinical trials. But if patient centricity becomes patient burden, it causes a deficit with patients themselves. If data is the currency in clinical trials, then patients are the medium. As a finite resource, participant time and emotional investment into a clinical trial is immeasurable and should not be idly wasted.
For a long time, industry was accused of not considering participants at all in clinical trials, and the patient-centric movement was born. Recent discussions with veteran industry professionals indicate a real desire to move away from overt patient burden in the guise of centricity, and into the reality of clinical trial participation.
Even a pharma CEO recently noted that sometimes, patients just don’t want all eyes focused on them. They just want to live their lives. And feel the same anxieties we all do.
Lisa Henderson is Editor-in-Chief of Applied Clinical Trials. She can be reached at lhenderson@mjhlifesciences.com.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.